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Abstract 
Background The Valsalva Manoeuvre (VM) is used to treat Supraventricular 
tachycardia (SVT) by inducing a vagal response (drop in heart rate). Body position 
and how the VM strain is generated may affect the efficacy of this treatment. There is 
debate as to the best position in which to carry out the VM and how the strain should 
be delivered in practice. We aimed to compare vagal responses induced with supine 
and modified VMs using strains delivered with a standardised manometer or novel 
Valsalva Assist Device (VAD), a simple device to provide resistance to exhalation, in 
healthy volunteers. 
Methods We did a repeated measures randomised trial of four VMs (2 Supine VM 
and 2 modified VM’s) in healthy adult volunteers with strains delivered using an 
adapted sphygmomanometer (manometer) or a VAD. Changes in heart rate were 
monitored and compared between the techniques and devices. The pressure and 
duration of VM strains achieved with the VAD and manometer and any adverse 
events were also compared. The trial was conducted at the Royal Devon & Exeter 
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Hospital over a four month period (November to February 2018), was registered with 
ClinicalTrials.gov (NCT03298880) and approved by the University of Exeter Medical 
School Research ethics committee. 
Results 75 healthy participants aged 19-55 were recruited over a four month period. 
A mixed-effects linear regression was completed showing the modified VM resulted 
in a significantly greater drop in heart rate of 3.8 bpm compared to the supine VM 
(p=0.002, CI 2.2-5.4). VM strains produced by the VAD were of a similar pressure 
but of slightly shorter duration and resulted in a statistically smaller drop in heart rate 
of 1.9 bpm (p=0.01, CI 0.4-3.4) compared to the manometer.  
Conclusions Modified VM was associated with a greater drop in heart rate than a 
supine VM without an increase in adverse events in healthy volunteers. The Valsalva 
Assist Device can be used to safely generate the recommended VM strain pressure, 
but produced a smaller drop in heart rate compared to a manometer and requires 
modification to enable the recommended strain duration to be achieved consistently. 
 
 
Introduction 
The Valsalva manoeuvre (VM) is an internationally recommended first-line treatment 
for haemodynamically stable supraventricular tachycardia (SVT).[1] The VM involves 
an exhalation strain against resistance which causes a reflex slowing of heart rate 
mediated by the vagus nerve. The highest VM cardioversion rates in emergency 
medicine practice to date have been achieved in a study (REVERT) using a postural 
modification and a manometer delivered strain compared with semi-recumbent 
controls. In this study, intervention patients with SVT undertook Valsalva strains 
using an adapted sphygmomanometer, blowing for 15 seconds at 40mmHg in a 
semi-recumbent position before immediate supine repositioning with passive leg 
raise at the end of the strain.[2] 
However there is debate whether this modification has any advantage over a purely 
supine VM which is associated with a greater vagal response in healthy volunteers 
compared to sitting and Trendelenberg position VMs [3] and may reduce the risk of 
adverse events.[4] Adapted manual sphygmomanometers are also not routinely 
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available for VMs carried out in normal practice and whilst surrogates such as 
blowing on empty syringes are commonly used, they have been shown to be 
unreliable.[5] 
A simple hand held Valsalva Assist Device (VAD) has been developed to provide 
40mmHg resistance to exhalation and is available as a CE marked device (‘Valse-
Valve’ Valsalva Assist Device, Meditech Systems Limited, Shrublands Estate, 
Sherstock, Shaftesbury, Dorset, SP7 9PT. See figure 1). This device has a mouth 
piece, a pressure indicator and an air leak to prevent mouth pressure only generated 
strains (pressure not transmitted to the thorax). However it has not been tested 
against a sphygmomanometer in healthy volunteers or in the postures that might be 
used in clinical practice. Such a device used in clinical practice, would be 
advantageous to control and standardise strains and could also carry clear 
instructions for the recommended VM posture and strain duration.  
We conducted a repeated measures trial to compare the vagal responses (drop in 
heart rate) and strain characteristics achieved by healthy volunteers performing VMs 
in both supine and modified positions using the VAD and adapted 
sphygmomanometer (‘manometer’). Our objectives were to compare the vagal 
response to modified and supine VMs and to assess the performance of the VAD. 
 
Methods 
Participants: 
The study was approved by the University of Exeter ethics committee and registered 
with ClinicalTrial.gov (NCT03298880) prior to commencement of recruitment. 
Healthy adult volunteers (18-60 years) from University of Exeter or Royal Devon & 
Exeter Hospital NHS Foundation Trust staff were invited to take part through posters 
and social media.  All participants were screened for eligibility (figure 2) and provided 
informed written consent prior to participation.  
 
Screening involved physical examination, including observations of pulse, oxygen 
saturations, respiratory rate and blood pressure and the recording of a 12 lead ECG. 
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Testing was conducted in the clinical research facility (CRF) of the Royal Devon & 
Exeter Hospital, according to a strict trial protocol.  
 
Sample Size Calculations: Previous volunteer studies have suggested a difference of 
at least 3 beats per minute as an important difference between techniques.[3] We 
therefore powered our study to detect a difference of 4 beats/min, also taking into 
account informal pilot work suggesting at least this level of difference might be 
expected between techniques whilst ensuring a reasonable size study population 
and appropriately narrow confidence intervals. Calculations were based on a simple 
paired t-test using the standard deviations reported by G Smith et al in a similar 
study (about 12 for both individual measures and for differences between measures). 
With these parameters, a sample size of at least 73 participants would provide 80% 
power at the 5% level of significance. We planned to recruit a total of 75 participants 
in case of unexpected drop outs or device failure. 
 
Procedures: 
We conducted a randomised repeated measures trial between November 1, 2017 
and February 5, 2018 with participants undergoing a total of four VMs of the 
following variations in random order, stratified by all possible orders: 
Study Valsalva Manoeuvre Interventions: 
1. Supine VM using manometer. Supine Valsalva strain using a manometer 
visible to the participant with a target of 40mmHg for 15 seconds. 
2. Modified VM using manometer. Semi-recumbent (at 45 degrees) Valsalva 
strain using a manometer visible to the participant with a target of 40mmHg 
for 15 seconds followed by supine positioning and passive 45 degree leg lift 
immediately at the end of the strain for a further 15 seconds. 
3. Supine VM using device. Supine Valsalva strain using the device connected 
to manometer invisible to the participant but visible to a researcher for 15 
seconds. 
4. Modified VM using device. Semi-recumbent (at 45 degrees) Valsalva strain 
using the device connected to manometer invisible to the participant but 
visible to a researcher for 15 seconds followed by supine positioning and 
passive 45 degree leg lift immediately at the end of the strain for a further 15 
seconds. 
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All testing was performed on a standard hospital trolley with a manually adjustable 
back rest. A 45 degree angle template guide was used to ensure consistent back 
rest and leg elevation angles. Participants lay at rest for 5 minutes prior to testing to 
ensure baseline resting heart rate was achieved. Participants were read clear, 
standardised instructions before each manoeuvre and target pressures were marked 
on the manometer and device gauges. No practices were allowed. A new device and 
a new 92cm length of green oxygen bubble tubing, for the manometer, were used for 
each participant. 
 
A stop watch was used to time all procedures and was visible to participants and 
researchers. Participants were instructed to stop blowing after the 15 second strain 
but no other encouragement or instruction was allowed. For safety, participants were 
not allowed to blow more than 50mmHg, as measured on the manometer, whether 
using the manometer or device to generate the strain. It was planned that in event of 
device malfunction (ie it provides no resistance or resistance is greater than 
50mmHg), the VM would be abandoned and the malfunction recorded as an adverse 
incident. The particular manoeuvre would then be restarted using a new device, if 
the participant was happy to continue. 
 
There was a three minute washout period between strains including two minutes rest 
after any change in posture. Continuous 3 lead ECG monitoring on the same, 
previously calibrated, print enabled defibrillator (Smart Biphasic AED, Philips 
Heartstart XL) was used to assess heart rate during the manoeuvre. Standard ECG 
rhythm strip traces (25mm/second) were printed for 45 seconds (15 seconds before, 
during and 15 seconds after each VM). They were marked at the onset of each 
Valsalva strain, labelled with a code and subsequently analysed in batches, blind to 
technique according to the method described by G Smith et al.[3] These traces were 
second read by another researcher, who was not part of the study team nor present 
at testing and also blind to allocation.  
 
Pre-manoeuvre heart rates were determined by calculating the mean R-R interval of 
the 10 beats preceding each manoeuvre before converting it to heart rate in 
beats/minute ((25/mean R-R interval)x60). The lowest post manoeuvre heat rate was 
determined by measuring and recording the longest R-R interval during and up to 15 
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seconds post manoeuvre, converted to a heart rate in beats per minute ((25/longest 
R-R interval)x60). The difference between the pre and post manoeuvre heat rate 
indicated the degree of vagal tone or slowing of heart rate induced by each 
manoeuvre. Where there was disagreement in ECG measurements between the two 
readers, the mean of the two figures was taken. The peak sustained strain pressures 
achieved, as observed on the manometer and duration of longest strain attempt 
during all VMs were also recorded on a standard report card. 
 
Participants were monitored for any adverse events. Participants who felt unwell or 
who developed any significant or persistent ECG abnormalities were immediately 
withdrawn from further testing and appropriate further clinical assessment arranged. 
All adverse events were recorded, graded and reported according to Good Clinical 
Practice guidelines.  
 
Statistical Analysis: 
The heart rates measured under each of the four testing scenarios were summarised 
appropriately, e.g. mean and SD, with the expectation that heart rate would be 
approximately normally distributed. The following comparisons of drop in heart rate 
were planned: 
1. Supine VM vs modified VM (recognising that this comparison may or may not be 
different according to how the strain was generated – manometer or device) 
2. Manometer vs device (recognising that this comparison may or may not be 
different according to the posture used – supine or modified) 
Analysis was based on mixed effects linear regression (with appropriate prior 
assessment of assumptions, eg Normality), assessing post-VM heart rate with 
individual as a random effect, and posture (supine/modified) and strain method 
(manometer/device) as fixed effects.  An interaction term (posture x strain method) 
was examined to consider whether there was any evidence of a differential effect (of 
strain method according to posture, or equivalently posture according to strain 
method), but was planned to be dropped from the model if p>0.1 (no evidence of 
interaction).  If the interaction term was to be retained then comparison 1 between 
postures would be presented separately by strain method, and comparison 2 
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between strain methods would be presented separately by posture type; otherwise 
the two comparisons would be presented overall. 
Two versions of the model were used, one adjusting for pre-VM heart rate as a 
covariate, the other not doing so.  The pre-VM heart rate was measured having 
assumed the relevant starting position for the next manoeuvre, and was 
(unsurprisingly) lower for the supine manoeuvres than the modified versions, which 
start in a semi-recumbent position.  Hence these pre-VM heart rates are not true 
baselines comparable across the four scenarios.  Moreover, since all four 
manoeuvres were undertaken by each person (hence essentially comparing results 
“within” person), the starting heart rate adds little to statistical efficiency. 
Results 
80 volunteers were screened and 5 were excluded (heart murmurs (2), ECG 
abnormalities (2) and participant on medication (1)). 75 healthy participants aged 19-
55 years (mean 26) underwent trial VMs. 45 (60%) were female. All participants 
completed all four VMs and there was no missing data. There was one device failure 
where the pressure observed by manometer was 60mmHg while the device was 
showing a pressure 40mmHg. This attempt was abandoned and redone with a new 
device and reported as an adverse event as described in the methods. 
Agreement of readers 
For the traces analysed for 10 beats prior to the manoeuvre, the two readers had 
very good agreement for measuring the relevant interval: they both reported overall 
means of 180.8mm, with 71% of the 300 readings being identical.  99% of readings 
were within 1mm and the (single) worst discepancy was 2.5mm.  For the post-
manoeuvre readings of the longest R-R interval, the two readers both recorded 
overall means of 27.8mm, with 80% of readings identical and 100% within 1mm. As 
agreement of the trace readings were very good (intraclass correlation 0.999 or 
higher), a simple average of the two readings was subsequently used in the 
analyses. 
Effects on Heart Rate  
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All manoeuvres were associated with a substantial drop in heart rate. Mean heart 
rates observed for the four VMs are summarised in table 1 together with Valsalva 
ratios (highest heart rate/lowest heart rate recorded during the VM)   
 
Table 1. Mean heart rate (sd) with study Valsalva Manoeuvres 
Study VM Pre-VM HR Post-VM HR Difference VR 
Supine with 
manometer 
82.8 (15.8) 55.7 (9.4) 27.1 (12.4) 1.49 
Modified with 
manometer 
88.1 (14.4) 53.7 (10.9) 34.4 (15.2) 1.64 
Supine with 
VAD 
83.1 (14.7) 58.0 (10.0) 25.1 (9.3) 1.43 
Modified with 
VAD 
88.4 (15.6) 55.4 (9.7) 32.9 (14.3) 1.60 
All supine 83.0 56.9 26.1 1.47 
All modified 88.3 54.6 33.7 1.66 
All 
manometer 
85.5 54.7 30.7 1.59 
All VAD 85.8 56.7 29.10 1.53 
 
n= 75 
VR: Valsalva Ratio (pre-VM HR/post-VM HR) 
 
The table also shows the “marginal” results for all supine manoeuvres (combining 
manometer and device results); all modified manoeuvres (similarly), all manometer 
use (combining supine and modified manoeuvres) and all VAD use (similarly). 
These unadjusted means in table 1 suggest that the modified manoeuvre was 
associated with a greater reduction in heart rate than the supine manoeuvre, a 
difference of about 8 bpm. Moreover this difference is consistent across strain 
methods, with a similar difference whether the manometer or device is used.  The 
table also suggests a small difference between the two strain methods, with a slightly 
larger reduction in heart rate for the manometer compared with the VAD, again with 
consistency across the two postures used. 
The mixed effects regression (including pre-VM heart rate as a covariate) resulted in 
a small interaction (strain method x posture of VM) with a p-value of 0.70, hence was 
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dropped as planned. The resulting model then showed a significant effect for VM 
posture used, with the modified version reducing heart rate by 3.8 bpm more than 
the supine version (95% confidence interval 2.2 to 5.4; p<0.001).  The strain method 
also showed a significant effect (albeit weaker), with the manometer reducing heart 
rate by 1.9 bpm more than the VAD (95% CI 0.4 to 3.4; p=0.01). Shown in table 2 
Table 2.  Adjusted differences in fall of heart rate between postures and strain 
methods using mixed effects regression to adjusting for baseline (pre-VM) 
heart rate 
Comparison Difference in bpm 
(95%CI) 
P value 
Supine v Modified VM 3.8 (2.2-5.4)* P<0.001 
VAD v Manometer 1.9 (0.4-3.4)** P=0.01 
*Lower post VM HR with modified VM 
**Lower post VM HR with manometer 
 
Repeating the regression without the pre-VM heart rate as a covariate produced 
similar results: a small non-significant interaction (p=0.69), and significant benefits 
for the modified posture (2.3 bpm, 95% CI 0.8 to 3.8; p=0.003) and manometer (2.0 
bpm, 95% CI 0.5 to 3.5; p=0.01). 
 
  
Strain Characteristics (See table 3) 
The mean strain pressures delivered by manometer and VAD were similar (39.96 vs 
42.46 mmHg) but manometer was more precise with 97% of participants straining 
between 35-45mmHg compared to 75% when using the VAD. The use of VAD was 
also associated with significantly shorter total duration of strain and anecdotally was 
due to subjects running out of breath. This was particularly evident in females with 
only about a third of female participants achieving a full 15 second strain with the 
device compared to 95% of males (data not shown).  
Table 3.  Mean Pressure and Strain Duration Characteristics 
Strain Method Mean Peak Pressure 
(mmHg) 
Proportion 
in35-
Mean Duration 
(secs) 
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45mmHg 
range (%) 
Manometer 39.96 97 14.91 
VAD  42.46 745 13.70 
 
 
 
Adverse Events: (See table 4) 
34 (11%) of the 300 VM undertaken were associated with symptoms reported during 
the attempts. All of these were transient and did not prevent completion of VMs and 
were similar between the four different VM under investigation. The most common 
side effect was a headache and light-headedness.  No serious adverse events were 
recorded. 
Table 4. Recorded adverse events by allocation 
 The Modified VM The Supine VM 
 VAD Manometer VAD Manometer 
Lightheaded 3 2 1 1 
Tingling lips 1   1 
Ectopic 1    
Rib strain 1    
Head rush    1 
Unable to blow 
into tube 
   1 
Headache 1 6 4 6 
Vision changes    2 
Chest discomfort 1    
Device failure   1  
Totals 8/150 8/150 6/150 12/150 
Totals Modified 
and Supine 
16/150 18/150 
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Discussion 
Our results demonstrate the physiological advantage of the described modified 
Valsalva over a purely supine VM. This postural modification was associated with a 
greater vagal response, shown by the absolute and relative drop in heart rate 
compared to the supine VM. Despite supine positioning being associated with a 
lower initial heart rate (likely because of initial increased vagal tone), the 
exaggerated effects on venous return resulting from semi-recumbent position in the 
strain phase and leg elevation in the supine relaxation phase (Valsalva stage 3) 
resulted in more intense vagal stimulation overall with the modified VM.  
 
Previous work has suggested that vagal techniques associated with a greater drop in 
heart rate and so larger Valsalva ratio, are correlated with a greater chance of SVT 
being terminated when that vagal manoeuvre is used to treat this arrhythmia.[6] So, 
although caution must be employed in extrapolating volunteer studies, demonstration 
of a significantly greater drop in heart rate with the modified VM in this study, is 
consistent with the efficacy of this postural modification in clinical trials.[2,7] and 
benefits of a modified VM over a purely supine technique.  
 
Although straining in upright postures is in theory associated with a greater drop in 
blood pressure and an increased risk of syncope during straining [7], this 
complication was not seen in our study which used a controlled and defined strain 
and is consistent with our experience of the modified VM in clinical practise and 
trials. There were no serious adverse events and the number of non-serious adverse 
events was similar between the two different posture groups. We believe this study 
therefore further supports the case for routine use of a modified VM as described, 
over a supine VM. 
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Overall, VMs with VAD generated strains resulted in a meaningful fall in heart rate of 
29bpm. This is greater than that seen in similar volunteer studies using a manometer 
[3, 8] The VAD however, did not perform quite as well as the manometer in terms of 
vagal response in our study. Although the difference in drop of mean heart rate 
between these strain methods just reached statistical significance, it was less than 
our previously stated clinically meaningful difference of 4 bpm (which was also 
excluded from the 95% confidence interval) and it is debateable whether this small 
difference. would affect cardioversion rates if it were replicated in clinical practice  
 
The device produced a similar mean pressure of strain. Although the variation of 
pressures was greater than with manometer, this was within a clinically appropriate 
range and considerably better than that seen with use of a syringe.[4] The VAD 
however, was associated with significantly shorter strain durations than strains 
utilizing the manometer. This was almost certainly due to the pre-designed air leak 
which was probably a little too large for most volunteers compared to the manometer 
which is a sealed system with no leak.  Shorter durations of strain were seen most 
with VAD delivered strains by female participants. Female sex is associated with a 
physiologically lower functional residual lung capacity and supports the theory that 
the device leak was the cause for the reduced strain duration observed with the 
VAD. This degree of leak and shorter duration of VM strain might account for the 
devices marginally reduced effect on heart rate. This has been fed back to the 
manufacturer to consider refinements to their design. There was no significant 
difference but a trend towards a lower number of adverse events in the VAD group. 
Further study could reassess performance of such device modifications and 
compare it again to the manometer or to the syringe, as the most commonly used 
alternative in practice. 
 
We conducted our study on mainly young, healthy volunteers with a slight 
preponderance to females. This is the demographic of many patients with SVT 
however there is a second peak of incidence in older age, often in patients with 
associated co-morbidities and so consideration should also be given to repeating this 
study and assessing VAD performance in the older population.  
14 
 
 
Finally, findings from this volunteer study using the VAD should not be used alone in 
changing the care of patients with SVT. Other work will be needed to assess the 
performance of such devices in clinical practice A feasibility trial is currently 
underway to look at use of the VAD (after modifications) by paramedics in the South 
West of England to treat patients with SVT (EVADE Study, NCT03514628). 
 
Conclusions 
This study indicates that a modified VM results in a greater vagal response than a 
standard supine VM with no increase in adverse effects when used with a controlled 
strain in healthy volunteers. Our findings give support for the physiological 
advantage of this specific manoeuvre over a purely supine VM.  
We have also shown a simple hand held device can be used to generate 
recommended VM strain pressures but its use in volunteers resulted in shorter strain 
durations and a slightly smaller drop in heart rate compared to a modified 
sphygmomanometer. Refinements to this device may improve its function further and 
allow it to be assessed in clinical practice to treat SVT. 
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